The Board approved inter alia financial results for the quarter and half year ended September 30 2026.

Windlas Biotech Limited Reg. Off.: 40/1, Mohabewala Industrial Area Dehradun, Uttarakhand 248 110, India Tel.:+91-135-6608000-30, Fax:+91-135-6608199 Corp. Off.: 705-706, Vatika Professional Point, Sector-66, Golf Course Ext. Road, Gurgaon, Haryana 122 001, India Tel.:+91-124-2821030 CIN-L74899UR2001PLC033407 November 5, 2026 To To Listing / Compliance Department Listing / Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street, Mumbai – 400 001 Bandra Kurla Complex Bandra (E), Mumbai – 400 051 BSE CODE: 543329 NSE SYMBOL: WINDLAS Dear Sir/ Madam, Sub: Outcome of the Board Meeting held on November 5, 2026 Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), as amended from time to time, please be informed that the Board of Directors of the Company, at its meeting held today, inter alia, considered and approved, the following: 1. Financial Results The Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026, prepared in accordance with the Indian Accounting Standards (Ind AS), were considered, approved and taken on record. A copy of the said Financial Results together with the Limited Review Report issued by M/s J C Bhalla & Co, Statutory Auditors of the Company, is enclosed as Annexure I. 2. Resignation from the position of Whole-time Director and Directorship of the Company The Board has noted and accepted the resignation of Mr. Ashok Kumar Windlass (DIN: 00011451) from the position of Whole-time Director and Director of the Company with effect from November 5, 2026 at 10.00 A.M, due to the Company's long-term succession planning. Consequently, he shall also cease to be a Member of Corporate Social Responsibility Committee of the Company. The letter of resignation received from Mr. Ashok Kumar Windlass is enclosed as Annexure II. 3. Appointment of Senior Management Personnel Based on the recommendation of the Nomination and Remuneration Committee and the Audit Committee, the Board of Directors has approved the appointment of Mr. Ashok Kumar Windlass, Founder President, as Senior Management Personnel of the Company, effective from November 6, 2026, subject to the approval by the shareholders of the Company. 4. Appointment of Chairman of the Board of Directors The Board of Directors has approved the appointment of Mr. Hitesh Windlass (DIN: 02030941), Managing Director and Promoter of the Company as the Chairman of the Board with effect from November 5, 2026. The details as required under Regulation 30 read with Para A of Schedule III (Part A) of the Listing Regulations, along with the additional details required under the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026, on continuous disclosure requirements, relating to aforesaid appointments are annexed as Annexure III. www.windlas.com Windlas Biotech Limited Reg. Off.: 40/1, Mohabewala Industrial Area Dehradun, Uttarakhand 248 110, India Tel.:+91-135-6608000-30, Fax:+91-135-6608199 Corp. Off.: 705-706, Vatika Professional Point, Sector-66, Golf Course Ext. Road, Gurgaon, Haryana 122 001, India Tel.:+91-124-2821030 CIN-L74899UR2001PLC033407 The meeting of the Board of Directors commenced at 2.30 P.M. and concluded at 3.35 P.M. Kindly take the same on record. Thanking you, Yours faithfully, For Windlas Biotech Limited Ananta Narayan Panda Company Secretary & Compliance Officer Encl: as above www.windlas.com J C BHALLA & CO. CHARTERED ACCOUNTANTS BRANCH OFFICE: B-5, SECTOR-6, NCIDA - 201 301 (U.P.) TEL. : +91 - 120 - 4241000, FAX : +91-120-4241007 E-MAIL . taxaid@]cbhalla.com Independent Auditor's Limited Review Report on the Quarterly Unaudited Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended The Board of Directors Windlas Biotech Limited We have reviewed the accompanying statement of unaudited financial results of Windlas Biotech Limited ("the Company") for the quarter and six months ended September 30, 2026 ("the Statement"), attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended' This statement is the responsibility of the Company's management and has been approved by the Board of Directors. The preparation of the statement is in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the applicable Indian Accounting Standards (Ind-AS)- prescribed under section 133 of the Companies Act,2013, read with relevant rules issued thereunder, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including, the manner in which itis to be disclosed, or that it contains any material misstatement. HEAD OFFICE : B-17, Maharani Bagh, New Delhi - 110065 5. Other Matter We draw attention to Note 9 to the accompanying Statement, which states that pursuant to the filing for dissolution of Windlas Inc., USA, a wholly owned non- operating subsidiary of the Company, with the Delaware Division of Corporations and pursuant to the Board Resolution dated February 5, 2026, the said subsidiary stands dissolved with effect from March 31, 2026. Accordingly, with effect from April 1, 2026, the Company is no longer required to prepare consolidated financial statements. Our conclusion is not modified in respect of this matter. ForJ CBhalla & Co. Anshuman Mallick Partner Membership No. - 54770 UDIN: 2.6 So\ s Z PAGBIE Place: Noida Date: November 05, 2026 Windlas Biotech Limited CIN: L74899UR2001PLC033407 Registered office: 40/1 Mohabewala Industrial Area, SBI Road,Dehradun-248110 (Uttarakhand), India Telephone No: 0135-6608000| Email ID: cs@windlasbiotech.com| Website: www.windlasbiotech.com Statement of unaudited financial results for the quarter and six months ended 30th September'2026 (All amounts in Indian Rupees in millions, unless otherwise stated) Quarter Ended Six months ended Year Ended Particulars 30th September, 30th June, 30th September, 30th September, 30th September, 31st March, 2026 2026 2025 2026 2025 2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) Revenue from Operations 2 ,639.08 2 ,480.99 2 ,223.98 5 ,120.07 4 ,324.88 9 ,040.89 Other Income 3 8.61 5 1.13 3 6.45 8 9.74 8 8.84 1 78.04 Total Income 2 ,677.69 2 ,532.12 2 ,260.43 5 ,209.81 4 ,413.72 9 ,218.93 Expenses Cost of Material Consumed 1 ,841.71 1 ,687.41 1 ,442.87 3 [Showing first 8,000 characters — download PDF for full document]